Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. is a Japan-based global specialty pharmaceutical and biotechnology company dedicated to improving human health and well-being worldwide. Headquartered in Chiyoda-ku, Tokyo, Japan, the company's mission is to create new value through advances in life sciences and technologies, driven by a vision to deliver life-changing value that ultimately makes people smile.

The company focuses on developing innovative biopharmaceuticals across several core therapeutic areas, including oncology, nephrology, central nervous system disorders, immunology/allergy, and rare diseases. Its portfolio features key products such as Crysvita for rare bone disorders, Poteligeo for certain lymphomas, and Nourianz for Parkinson's disease. Kyowa Kirin also develops and commercializes biosimilars and diagnostics, leveraging its expertise in state-of-the-art antibody technologies.

In recent developments, Kyowa Kirin announced the discontinuation of all clinical trials for rocatinlimab in March 2026 due to emerging safety concerns related to malignancies. The company continues to expand its global footprint and pipeline, notably acquiring Orchard Therapeutics in October 2023 to bolster its capabilities in hematopoietic stem cell gene therapy. Leadership changes effective March 2025/2026 will see Masashi Miyamoto transition to Chairman and CEO, with Abdul Mullick appointed President and COO, marking the first time a non-Japanese executive has held such a senior operational role within the company.